Stock analysts at Guggenheim started coverage on shares of Metsera (NASDAQ:MTSR – Get Free Report) in a research note issued to investors on Tuesday,Briefing.com Automated Import reports. The brokerage set a “buy” rating and a $56.00 price target on the stock. Guggenheim’s price objective suggests a potential upside of 87.86% from the company’s current price.
A number of other equities analysts have also commented on the stock. Evercore ISI initiated coverage on shares of Metsera in a research report on Tuesday. They set an “outperform” rating on the stock. Bank of America began coverage on Metsera in a research note on Tuesday. They issued a “buy” rating and a $38.00 price objective on the stock.
Read Our Latest Report on MTSR
Metsera Trading Down 5.8 %
Metsera Company Profile
Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.
Read More
- Five stocks we like better than Metsera
- 3 Natural Gas Stocks That Offer Great Dividend Yields
- Confluent: How Data Streaming May Transform AI
- 3 Stocks to Protect Your Portfolio from the Coronavirus Contagion
- The Behemoth BlackRock’s Next Trillion Comes From Private Assets
- Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
- Rivian’s Rough Patch: Is the Dip a Doorway to Long-Term Gains?
Receive News & Ratings for Metsera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Metsera and related companies with MarketBeat.com's FREE daily email newsletter.
